Veracyte, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Veracyte, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 8.3 times. Higher than 94% of Healthcare companies in United States.
- Debt Due Cover Ratio: Debt due within a year is covered 33.6 times by its yearly operating cash. Higher than 93% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $39 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 89% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
8.3×Over the last 3 years its own operating cash covered its investment spending (capex) 8.3 times.
Higher than 94% of Healthcare companies in United States.
Cash Locked Ratio
$12For every $100 of sales, $12 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $16 tied up three years earlier.
Less money tied up than 77% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$47Sales grew 74% in 3 years; of every extra $100 of sales, $47 became extra profit.
Higher than 68% of Healthcare companies in United States.
Asset Productivity Ratio
+74% / +22%In 3 years sales changed by +74% while total assets changed by +22%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
33.6×Debt due within a year is covered 33.6 times by its yearly operating cash.
Higher than 93% of Healthcare companies in United States.
Cash Cushion Ratio
+10%Cash, after subtracting all debt, equals 10% of its market value (net cash).
Higher than 50% of Healthcare companies in United States.
Tangible Assets Ratio
39%Of every $100 the company owns, $39 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 89% of Healthcare companies in United States.
Tangible Net Worth Ratio
35%Of every $100 of net worth, $35 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 59% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Veracyte, Inc. owes $0.07 for every $1 it owns. Net profit rose 175% in the year to Dec 2025.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
34.2Investors pay $34.2 for every $1 of Veracyte, Inc.'s yearly profit, higher than 63% of Healthcare companies in United States.
P/B ratio
2.78The share price is 2.78 times Veracyte, Inc.'s book value per share, higher than 53% of Healthcare companies in United States.
Market cap
$3.9 BThe total market value of all of Veracyte, Inc.'s shares at today's price (share price × number of shares), larger than 82% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$1.4 BWhat Veracyte, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$17.27Net worth divided by the number of shares. The share price of $47.93 is 2.8 times this, which is the P/B above.
Return on equity (ROE)
8.8%Veracyte, Inc. earned 8.8% on its shareholders' money over the last year, higher than 82% of Healthcare companies in United States.
Owes vs Owns
0.07×Veracyte, Inc. owes $0.07 for every $1 it owns (low), lower than 93% of Healthcare companies in United States.
Dividend yield
NoneVeracyte, Inc. does not currently pay a dividend.
Revenue growth
+16%Revenue rose 16% in the year to Dec 2025, and grew 20% a year on average over 3 years.
Profit growth
+175%Net profit rose 175% in the year to Dec 2025.
Profit margin
12.8%Veracyte, Inc. keeps $13 of every $100 of revenue as net profit.
Cash quality
2.1×Cash from Veracyte, Inc.'s business was 2.1× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
78282.0×Veracyte, Inc.'s operating profit covered its interest costs 78282.0 times in the year to Dec 2025.
Cash vs debt
Net cashVeracyte, Inc. held $373 M more cash than debt (net cash) at Dec 2025.
Questions
What is Veracyte, Inc.'s P/E ratio?
Investors pay $34.2 for every $1 of Veracyte, Inc.'s yearly profit, higher than 63% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Veracyte, Inc.: $3.9 B ÷ $1.4 B (30 Jun 2026) = 2.8.
What is Veracyte, Inc.'s return on equity?
Veracyte, Inc. earned 8.8% on its shareholders' money over the last year, higher than 82% of Healthcare companies in United States.
How much does Veracyte, Inc. owe compared with what it owns?
Veracyte, Inc. owes $0.07 for every $1 it owns (low), lower than 93% of Healthcare companies in United States.
Does Veracyte, Inc. pay a dividend?
No. Veracyte, Inc. does not currently pay a dividend.
Is Veracyte, Inc.'s revenue growing?
Revenue rose 16% in the year to Dec 2025, and grew 20% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.